Videos

The associate professor of medicine at University of Pennsylvania discussed new data from the BENEGENE-2 study of fidanacogene elaparvovec.

Simeone discussed the design of BASECAMP-1, an observational study for patients previously treated for solid tumors who are at a high risk of relapse.

Steven Pipe, MD, CS Mott Children’s Hospital, discussed the latest follow-up data from the HOPE-B study of the approved therapy, Hemgenix.

The chief executive officer of Cartherics discussed the company’s development of NK cell, T-cell, and macrophage cell therapies for various solid tumor indications.

The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed advantages of OTQ923 in treating SCD.

The director of clinical research at Sierra Eye Associates discussed data from the phase 1/2 PRISM study.

The director of the CCU/ICU at Saint John’s Health Center discussed updated data from a phase 1/2 trial of agenT-797.

The associate professor of medicine at Siteman Cancer Center and WUSTL discussed further research to be done with CAR T-cell therapies.

The chief medical and scientific officer of Tessa Therapeutics discussed data from the BESTA and CHARIOT studies presented at ASH 2022.

The clinician scientist at St. Jude Children’s Research Hospital discussed the session on cell therapies in acute leukemias and Hodgkin lymphoma she moderated at ASH 2022.

The assistant member at St. Jude Children’s Research Hospital discussed the ASH 2022 basic and translational science session she moderated.

Brent Warner, president, gene therapy, Poseida Therapeutics, discussed data on the preclinical P-FVIII-101 presented at ASH 2022.

Ying Huang, chief executive officer, Legend Biotech, discussed new data from the CARTIFAN-1 and CARTITUDE-2 studies.

The associate professor of medicine from University of Pennsylvania discussed updated data on huCART19-IL18 presented at the ASH 2022 meeting.

The assistant member at St. Jude Children’s Research Hospital discussed updated data from a phase 1 study being conducted at the hospital.

The associate professor of medicine at Siteman Cancer Center and WUSTL discussed updated data from a study of NT-I7 and tisa-cel presented at ASH 2022.

The professor of pediatric hematology/oncology at CS Mott Children’s Hospital discussed new follow-up data from the HOPE-B study presented at ASH 2022.

The associate attending physician at Memorial Sloan Kettering Cancer Center discussed updated data presented at the ASH 2022 meeting.

The assistant member of the department of malignant hematology at Moffitt Cancer Center discussed unmet needs in acute myeloid leukemia and how UCART123v1.2 may address these.

The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed new data from a phase 1/2 trial presented at ASH 2022.

The professor at University Hospital Dresden discussed data presented at the 2022 ASH meeting.

The study's primary investigator shared his thoughts on where CART-ddBCMA could fit within the treatment landscape.

The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed the session she moderated at the ASH 2022 annual meeting.

The associate professor from the Medical College of Wisconsin discussed how to address unmet needs with CAR T-cell therapies.

The chief medical officer of Forge Biologics discussed the potential advantages of the investigational combination therapy approach.

The chief medical officer of Forge Biologics discussed clinical data presented at ESGCT.

Shebli Atrash, MD, discussed the current landscape of available BCMA-directed therapies for treating multiple myeloma.

Paul discussed common symptoms and typical treatments for the 2 adverse events.